Dermata Therapeutics (DRMA) widens Q2 loss while preparing Tome skincare launch
Rhea-AI Filing Summary
Dermata Therapeutics reported second quarter 2026 results and detailed its pivot to a commercial-stage, direct-to-consumer skincare model centered on its Tome™ line. The company plans to launch its first product, Tome Foundational Treatment, on August 25, 2026, aiming to begin generating product revenue.
For the quarter ended June 30, 2026, Dermata reported a net loss of $2.97 million, compared with $1.70 million a year earlier, as selling, general and administrative expenses rose to $2.80 million from $1.16 million, driven by higher legal, marketing, commercialization, and employee costs. Research and development expenses declined to $0.21 million from $0.62 million as resources were reallocated toward commercialization. Cash and cash equivalents were $4.4 million as of June 30, 2026, versus $7.5 million at year-end 2025, and the company expects its current cash to fund operations into the fourth quarter of 2026.
Positive
- First product launch set for August 25, 2026, marking Dermata’s transition to commercial-stage revenue from its Tome Foundational Treatment.
- Cash and cash equivalents of $4.4 million as of June 30, 2026, with management expecting this to fund operations into the fourth quarter of 2026.
Negative
- Net loss widened to $2.97 million in Q2 2026 from $1.70 million in Q2 2025 as operating expenses increased.
- Selling, general and administrative expenses more than doubled to $2.80 million in Q2 2026 from $1.16 million, reflecting higher legal, marketing, and compensation costs.
- Cash balance declined to $4.4 million from $7.5 million over six months, despite $1.9 million of ATM financing proceeds.
Filing Explained
The filing adds that approximately
8-K Event Classification
Key Figures
Key Terms
direct-to-consumer financial
at-the-market financial
Bioneedle technical
Spongilla lacustris technical
forward-looking statements regulatory
Earnings Snapshot
Management expects current cash resources to be sufficient to fund operations into the fourth quarter of 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What strategic shift did Dermata Therapeutics (DRMA) describe in its latest report?
When will Dermata Therapeutics (DRMA) launch the Tome Foundational Treatment?
What were Dermata Therapeutics’ (DRMA) cash and cash equivalents as of June 30, 2026?
How did Dermata Therapeutics’ (DRMA) Q2 2026 net loss compare to Q2 2025?
What changes did Dermata Therapeutics (DRMA) report in R&D and SG&A expenses for Q2 2026?
How is Dermata Therapeutics (DRMA) funding its operations during 2026?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||
| The Capital Market | ||||
| The Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operation and Financial Condition.
On August 11, 2026, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the quarter ended June 30, 2026, and provided a corporate update. A copy of the press release is furnished under Item 2.02 as Exhibit 99.1.
The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release, dated August 11, 2026, issued by Dermata Therapeutics, Inc. entitled “Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026” | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
| -2- |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| DERMATA THERAPEUTICS, INC. | ||
| Dated: August 11, 2026 | By: | /s/ Gerald T. Proehl |
| Name: | Gerald T. Proehl | |
| Title: | President, Chairman and Chief Executive Officer | |
| -3- |
Exhibit 99.1
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 –
- Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand -
SAN DIEGO, CA, August 11, 2026 – Dermata Therapeutics, Inc. (Nasdaq: DRMA) (“Dermata,” or the “Company”), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2026.
“Over the past year, we have transformed Dermata through a strategic pivot to become a commercial-stage, direct-to-consumer skincare company,” commented Gerry Proehl, Dermata’s Chairman, President, and CEO. “This transition has been marked by significant execution across our organization, culminating in the development of our first commercial product, Tome Foundational Treatment, which we expect to start selling on August 25, 2026. As we prepare to enter the consumer skincare market, we believe we’ve identified the untapped ‘white space’ to launch our inaugural Tome product. We expect this launch will allow Dermata to begin generating revenues in the near future while continuing to build long-term value for our shareholders,” continued Mr. Proehl. “Looking ahead, we believe the opportunities before us extend well beyond the launch of a single product. Our direct-to-consumer platform provides the foundation to build lasting relationships with consumers, leverage data-driven insights to optimize marketing and customer engagement, and efficiently expand our product portfolio over time. We are excited to execute on our commercial strategy, establish a differentiated skincare brand, and create a scalable business that we believe can drive sustainable growth and enhance shareholder value for years to come,” concluded Mr. Proehl.
Corporate Highlights
| ● | Attended first trade show, Be+Well Beauty and Wellness Show in Las Vegas announcing its Tome brand. In June 2026, the Dermata team exhibited at the Be+Well Beauty and Wellness Show to officially launch the Tome brand and provided attendees with more information on the upcoming launch of its Foundational Treatment. The Be+Well conference hosts thousands of esthetics, spa, and wellness professionals with over 400+ brands in attendance. |
| ● | Began social media campaign for its new skincare brand, Tome. The Company recently unveiled the Tome brand’s official social media presence as part of the Company’s broader commercial launch strategy. These efforts are designed to increase brand awareness, engage prospective consumers, and support the successful ecommerce launch of the Company’s first commercial skincare product, Tome Foundational Treatment, expected on August 25, 2026. |
Anticipated Upcoming Milestones
| ● | Launch first direct-to-consumer (DTC) skincare product, Tome Foundational Treatment, expected on August 25, 2026. The Company has finished manufacturing and packaging for its Tome Foundational Treatment and is prepared for the upcoming commercial launch. The Company believes the Tome Foundational Treatment can be the base of any skincare routine, designed to renew the appearance of the skin and simplify skincare with a once-weekly application. |
| ● | Continue development of a second DTC product. The Company is also working on its second skincare product, a once weekly, over-the-counter (OTC) topical treatment for acne, which is expected to launch sometime after its Foundational Treatment. |
Second Quarter 2026 Financial Results
As of June 30, 2026, the Company had $4.4 million in cash and cash equivalents, compared to $7.5 million as of December 31, 2025. The $3.1 million decrease in cash and cash equivalents for the six months ended June 30, 2026, resulted from $4.9 million of cash used in operations, and $0.1 million of cash used in investing activities, offset by approximately $1.9 million of ATM financing proceeds. The Company expects its current cash resources to be sufficient to fund operations into the fourth quarter of 2026.
Research and development expenses were $0.2 million for the quarter ended June 30, 2026, compared to $0.6 million for the quarter ended June 30, 2025. The $0.4 million decrease in research and development expenses resulted primarily from the Company’s decision to prioritize the commercial launch of its first product, resulting in a decrease in research and development efforts during the three months ended June 30, 2026. As the Company continues to focus on branding, marketing, and manufacturing of its first commercial product, the Company reallocated its resources, including employee efforts, toward the pre-commercial launch and anticipates that research and development expenses will continue to decrease compared to prior periods.
Selling, general and administrative expenses were $2.8 million for the quarter ended June 30, 2026, compared to $1.2 million for the quarter ended June 30, 2025. The increase in selling, general and administrative expenses was primarily attributable to $0.7 million of increased legal fees, an increase of $0.6 million of marketing and other commercialization expenses, and an increase of $0.3 million of employee compensation attributable to a reallocation of employee efforts from research and development activities toward pre-commercial activities in anticipation of the Company’s first product launch.
About Dermata Therapeutics
Dermata Therapeutics is a scientific leader in dermatologic solutions that recently announced a strategic pivot from pharmaceutical development to begin focusing on the development and commercialization of direct-to-consumer skincare solutions. The Company is currently developing a first-of-its-kind skin renewal treatment which incorporates Dermata’s Bioneedle™. The Company expects to launch its first product on August 25, 2026, with additional innovations planned to follow. Dermata is headquartered in San Diego, California. For more information, or to join our mailing list, please visit http://www.dermatarx.com/.
About Tome
Tome is Dermata’s new skincare line focused on bringing about a new realm of skincare that is powerful, not punishing. Tome in its literal meaning is a large, important, scholarly book. Dermata intends to educate consumers with a brand that tells a skincare story rooted in science and history. Tome will consist of a line of skincare products incorporating its Bioneedle, utilizing Spongilla lacustris, a wild harvested, freshwater sponge that has evolved over millions of years, as the primary ingredient for consumers that are compelled by history and science to find the most potent products for their skincare routine. Dermata believes its Tome skincare line will simplify existing skincare routines with essential ingredients that deliver results, without the recovery associated with in-office treatments. Dermata expects to launch its first product, Tome Foundational Treatment, on August 25, 2026, with additional product launches planned to follow. Start your skincare story at www.tomeskincare.com.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata’s shift to prioritize DTC and OTC skincare products; the anticipated benefits of Dermata’s strategic shift to prioritize DTC and OTC skincare products, including acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer markets; the success, cost, and timing of the launch of its planned or future DTC and OTC products, including the Tome Foundational Treatment; the expected timing and success of any planned or future DTC and OTC product launches; expectations for the success of the Company’s products and their ability to generate revenue for the Company; the Company’s expectations with regard to current cash and cash equivalents and the amount of time it will fund operations; and other factors described in the Company’s filings with the Securities and Exchange Commission. These forward-looking statements are generally identified by the use of such words as “may,” “could,” “should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in product development and commercialization. For a discussion of these and other factors, please refer to Dermata’s filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
DERMATA THERAPEUTICS, INC.
Balance Sheets
| In thousands USD | June 30, 2026 | December 31, 2025 | ||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Cash and cash equivalents | $ | 4,413 | $ | 7,522 | ||||
| Prepaid expenses and other current assets | 594 | 342 | ||||||
| Inventories | 150 | - | ||||||
| Non-current assets | 164 | - | ||||||
| Total assets | 5,321 | 7,864 | ||||||
| Liabilities | ||||||||
| Accounts payable | 1,120 | 461 | ||||||
| Accrued liabilities | 713 | 1,180 | ||||||
| Total liabilities | 1,833 | 1,641 | ||||||
| Equity | 3,488 | 6,223 | ||||||
| Total liabilities and equity | $ | 5,321 | $ | 7,864 | ||||
DERMATA THERAPEUTICS, INC.
Statements of Operations
(unaudited)
| Quarter Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| In thousands, except share and per share data | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development (1) | $ | 213 | $ | 618 | $ | 596 | $ | 1,899 | ||||||||
| Selling, general and administrative (1) | 2,801 | 1,155 | 4,344 | 2,214 | ||||||||||||
| Total operating expenses | 3,014 | 1,773 | 4,940 | 4,113 | ||||||||||||
| Loss from operations | (3,014 | ) | (1,773 | ) | (4,940 | ) | (4,113 | ) | ||||||||
| Interest income | 47 | 72 | 125 | 108 | ||||||||||||
| Net loss | $ | (2,967 | ) | $ | (1,701 | ) | $ | (4,815 | ) | $ | (4,005 | ) | ||||
| Net loss per common share, basic and diluted | $ | (0.74 | ) | $ | (1.66 | ) | $ | (1.22 | ) | $ | (5.18 | ) | ||||
| Weighted average common shares outstanding, basic and diluted | 4,022,143 | 1,026,506 | 3,940,983 | 772,397 | ||||||||||||
| (1) Includes the following stock-based compensation expense | ||||||||||||||||
| Research and development | $ | 4 | $ | 8 | $ | 18 | $ | 16 | ||||||||
| Selling, general and administrative | $ | 38 | $ | 31 | $ | 67 | $ | 61 | ||||||||
Investor Contact:
Cliff Mastricola
Investor Relations
cmastricola@dermatarx.com